Quantitative Tissue Proteomics Analysis Reveals Versican as Potential Biomarker for Early-Stage Hepatocellular Carcinoma
Authors:
- Wael NaboulsiWNWael Naboulsi
- Dominik A. MeggerDMDominik A. Megger
- Thilo BrachtTBThilo Bracht
- Michael TurewiczMTMichael Turewicz
- Jörg F. SchlaakJSJörg F. Schlaak
- Andreas-Claudius HoffmannAHAndreas-Claudius Hoffmann
- Frank WeberFWFrank Weber
- Hideo A. BabaHBHideo A. Baba
- 18 December 2015
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 15 (1) , 38-47
Abstract
Hepatocellular carcinoma (HCC) is one of the most aggressive tumors, and the treatment outcome of this disease is improved when the cancer is diagnosed at an early stage. This requires biomarkers allowing an accurate and early tumor diagnosis. To identify potential markers for such applications, we analyzed a patient cohort consisting of 50 patients (50 HCC and 50 adjacent nontumorous tissue samples as controls) using two independent proteomics approaches. We performed label-free discovery analysis on 19 HCC and corresponding tissue samples. The data were analyzed considering events known to take place in early events of HCC development, such as abnormal regulation of Wnt/b-catenin and activation of receptor tyrosine kinases (RTKs). 31 proteins were selected for verification experiments. For this analysis, the second set of the patient cohort (31 HCC and corresponding tissue samples) was analyzed using selected (multiple) reaction monitoring (SRM/MRM). We present the overexpression of ATP-dependent RNA helicase (DDX39), Fibulin-5 (FBLN5), myristoylated alanine-rich C-kinase substrate (MARCKS), and Serpin H1 (SERPINH1) in HCC for the first time. We demonstrate Versican core protein (VCAN) to be significantly associated with well differentiated and low-stage HCC. We revealed for the first time the evidence of VCAN as a potential biomarker for early-HCC diagnosis.Keywords
Funding Information
- Nordrhein-Westfalen (z0911bt004e)
- European Regional Development Fund
This publication has 46 references indexed in Scilit:
- Selective isolation and analysis of glycoprotein fractions and their glycomes from hepatocellular carcinoma seraProteomics, 2013
- C/EBPα Is Up-regulated in a Subset of Hepatocellular Carcinomas and Plays a Role in Cell Growth and ProliferationGastroenterology, 2010
- Histological features of early hepatocellular carcinomas and their developmental process: for daily practical clinical applicationHepatology International, 2008
- A Quantitative Proteomic Approach for Identification of Potential Biomarkers in Hepatocellular CarcinomaJournal of Proteome Research, 2008
- Candidate Molecular Markers for Histological Diagnosis of Early Hepatocellular CarcinomaIntervirology, 2008
- Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: Analysis of 5,613 cases from a medical center in southern TaiwanInternational Journal of Cancer, 2007
- Proteomics for the early detection and treatment of hepatocellular carcinomaOncogene, 2006
- New therapies for hepatocellular carcinomaOncogene, 2006
- Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomasProceedings of the National Academy of Sciences, 1998
- Transforming growth factor—beta 1 (TGF-β1) and TGF-β1 receptors in normal, cirrhotic, and neoplastic human liversHepatology, 1995